Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Long-term follow-up confirms durable remission benefits from CAR-T therapy in blood cancers, strengthening confidence in lasting responses.
This report provides five-year follow-up from the ZUMA-3 phase 1/2 CAR-T study in relapsed or refractory B-cell acute lymphoblastic leukemia. Durable benefit across subgroups strengthens the long-term evidence base for brexucabtagene autoleucel, while remaining nonrandomized.
What the study was
- Study design
- Five-year follow-up of a phase 1/2 CAR-T trial
- Population
- Patients with relapsed or refractory B-cell acute lymphoblastic leukemia
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Transplantation and cellular therapy
Why it surfaced
Long-term CAR-T response and survival outcomes meet the novel-treatment flag rule and are directly relevant to a high-unmet-need hematologic malignancy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.